Telomerase: Biology and phase I trials

Lancet Oncology

Volumn 2, Issue 2, 2001, Pages 95-102

  Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

DRUG ANTAGONISM; HUMAN; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; REVIEW; TELOMERE;

CLINICAL TRIALS, PHASE I; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 0035262502     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00226-6     Document Type: Review

References (64)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
2. Garrett M.D., Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer. 35:1999;2010-2030.
3. Blackburn E.H. Structure and function of telomeres. Nature. 350:1991;569-572.
4. Hastie N.D., Dempster M., Dunlop M.G., et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 346:1990;866-868.
5. Reddel R.R. The role of senescence and immortalization in carcinogenesis. Carcinogenesis. 21:2000;477-484.
6. DePinho R.A. The age of cancer. Nature. 408:2000;248-254.
7. Blackburn E.H. Telomere states and cell fates. Nature. 408:2000;53-56.
8. Morin G.B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 59:1989;521-529.
9. Kim N.W., Piatyszek M.A., Prowse K.R., et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2015.
10. Feng J., Funk W.D., Wang S.-S., et al. The RNA component of human telomerase. Science. 269:1995;1236-1240.
11. Meyerson M., Counter C.M., Eaton E.N., et al. hEST2, theputative human telomerase catalytic subunit gene, isup-regulated in tumor cells and during immortalization. Cell. 90:1997;785-795.
12. Steensel van B., Lange de T. Control of telomere length by the human telomeric protein TRF1. Nature. 385:1997;740-743.
13. Kim S., Kaminker P., Campisi J. TIN2, a new regulator of telomere length in human cells. Nat Genet. 23:2000;405-412.
14. Zhu X.-D., Kuster B., Mann M., et al. Cell-cycle-regulated association of RAD50/MRE11/NBS1with TRF2 and human telomeres. Nat Genet. 25:2000;347-351.
15. Smith S., de Lange T. Tankyrase promotes telomere elongation in human cells. Curr Biol. 10:2000;1299-1302.
16. Griffith J.D., Comeau L., Rosenfield S., et al. Mammalian telomeres end in a large duplex loop. Cell. 97:1999;503-514.
17. Liu J.-P. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 13:1999;2091-2104.
18. Oh S., Song Y., Yim J., Kim T.K. The Wilms' tumour Itumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J Biol Chem. 274:1999;37473-37478.
19. Kolquist K.A., Ellisen L.W., Counter C.M., et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 19:1998;182-186.
20. Bryan T.M., Englezou A., Dalla-Pozza L., et al. Evidence foran alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. 3:1997;1271-1274.
21. Hahn W.C., Counter C.M., Lundberg A.S., et al. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.
22. Greenberg R.A., Chin A.C., Femino A., et al. Short dysfunctional telomeres impair tumorigenesis in the INK4D2/3 cancer prone mouse. Cell. 97:1999;515-525.
23. Holt S.E., Shay J.W. Role of telomerase in cellular proliferation and cancer. J Cell Physiol. 180:1999;10-18.
24. Urquidi V., Tarin D., Goodison S. Role of telomerase in cell senscence and oncogenesis. Annu Rev Med. 51:2000;65-79.
25. Kyo S., Takakura M., Ishikawa H., et al. Application of telomerase assay for the screening of cervical lesions. Cancer Res. 57:1997;1863-1867.
26. Zhang W., Kapusta L.R., Slingerland J.M., Klotz L.H. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res. 58:1998;619-621.
27. Soria J.-C., Gauthier L.R., Raymond E., et al. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res. 5:1999;971-975.
28. Chen X.-q, Bonnefoi H., Pelte M.-F., et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res. 6:2000;3823-3826.
29. Heine B., Hummel M., Muller M., et al. Non-radioactive measurement of telomerase activity in human bladder cancer, bladder washings, and in urine. J Pathol. 184:1998;71-76.
30. Tahara H., Yasui W., Tahara E., et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene. 18:1999;1561-1567.
31. Hiyama E., Hiyama K., Yokoyama T., et al. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med. 1:1995;249-255.
32. Marchetti A., Bertacca G., Buttitta F., et al. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res. 5:1999;2077-2081.
33. Clark G.M., Osborne C.K., Levitt D., et al. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 89:1997;1871-1874.
34. Faraoni I., Graziani G., Turriziani M., et al. Suppression of telomerase activity as an indicator of drug-induced cytotoxicity against cancer cells: in vitro studies with fresh human tumor samples. Lab Invest. 79:1999;993-1005.
35. Burger A.M., Double J.A., Newell D.R. Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer. 33:1997;638-644.
36. Bodnar A.G., Ouellette M., Frolkis M., et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352.
37. Zhu J., Wang H., Bishop M., Blackburn E.H. Telomerase extendsthe lifespan of virus-transformed human cells withoutnet telomere lengthening. Proc Natl Acad Sci USA. 96:1999;3723-3728.
38. Lee H.-W., Blasco M.A., Gottlieb G.J., et al. Essential role of mouse telomerase in highly proliferative organs. Nat Med. 392:1998;569-574.
39. Pitts A.E., Corey D.R. The telomerase challenge - an unusual problem in drug discovery. Drug Discovery Today. 4:1999;155-161.
40. Hamilton S.E., Simmons C.G., Kathiriya I.S., Corey D.R. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem Biol. 6:1999;343-351.
41. Herbert B.S., Pitts A.E., Baker S.I., et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA. 96:1999;14276-14281.
42. Mata J.E., Joshi S.S., Pirruccello S.J., et al. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol Appl Pharmacol. 144:1997;189-197.
43. Kondo S., Kondo Y., Li G., et al. Targeted therapy of human malignant glioma in a mouse model by 2-5 Aantisense directed against telomerase RNA. Oncogene. 16:1998;3323-3330.
44. Kondo Y., Koga S., Komata T., Kondo S. Treatment of prostate cancer in vivo with 2-5A-anti-telomerase RNA component. Oncogene. 19:2000;2205-2211.
45. Hahn W.C., Stewart S.A., Brooks M.W., et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 5:1999;1164-1170.
46. Zhang L., Mar V., Zhou W., et al. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 13:1999;2388-2399.
47. Strahl C., Blackburn E.H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol. 16:1996;53-65.
48. Gomez D.E., Tejera A.M., Olivero O.A. Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment. Biochem Biophys Res Commun. 246:1998;107-110.
49. Mergny J.-L., Helene C. G-quadruplex DNA: A target for drug design. Nat Med. 4:1998;1366-1367.
50. Sun D., Thompson B., Cathers B.E., et al. Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem. 40:1997;2113-2116.
51. Perry P.J., Reszka A.P., Wood A.A., et al. Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9, 10-diones. J Med Chem. 41:1998;4873-4884.
52. Harrison R.J., Gowan S.M., Kelland L.R., Neidle S. Human telomerase inhibition by substituted acridine derivatives. Bioorgan Med Chem Lett. 9:1999;2463-2468.
53. Izbicka E., Wheelhouse R.T., Raymond E., et al. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res. 59:1999;639-644.
54. Raymond E., Sun D., Izbicka E., et al. A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay. Br J Cancer. 80:1999;1332-1341.
55. Hayakawa N., Nozawa K., Ogawa A., et al. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry. 38:1999;11501-11507.
56. Naasani I., Seimiya H., Yamori T., Tsuruo T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 59:1999;4004-4011.
57. Naasani I., Seimiya H., Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun. 249:1998;391-396.
58. Coviello-McLaughlin G.M., Prowse K.R. Telomere length regulation during postnatal development and ageing in Mus spretus. Nucleic Acids Res. 25:1997;3051-3058.
59. Holt S.E., Glinsky V.V., Ivanova A.B., Glinsky G.V. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog. 25:1999;241-248.
60. Chu C.-T., Piatyszek M.A., Wong S.S.Y., et al. Telomerase activity and telomere lengths in the NCI cell panel of human cancer cell lines. Proc Am Assoc Cancer Res. 41:2000;3405. abstr.
61. Wong K.-K., Chang S., Weiler S.R., et al. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet. 26:2000;85-88.
62. Rufer N., Dragowska W., Thornbury G., et al. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol. 16:1998;743-747.
63. Remes K., Norrback K.-F., Rosenquist R., et al. Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse. Br J Cancer. 82:2000;601-607.
64. Brummendorf T.H., Holyoake T.L., Rufer N., et al. Prognostic implications of differences in telomere lengthbetween normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood. 95:2000;1883-1890.